Clinical trial · Interventional
ESPB Versus Perioperative Iv Lidocaine Infusion on Proinflammatory Cytokines in Breast Cancer Surgeries
Effect of Ultrasound Guided Erector Spinae Plane Block Versus Perioperative Intravenous Lidocaine Infusion on Proinflammatory Cytokines in Breast Cancer Surgeries
NCT07108959CI-TRIAL-00114783ESPBcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The present study aims to compare the effect of ESPB versus perioperative iv lidocaine infusion on proinflammatory cytokines in breast cancer surgeries.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| ESPB | — | UNRESOLVED | — |
| Lidocaine Infusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erector spinae plane block (Group E) | Procedure | — | UNRESOLVED |
| Lidocaine (drug) | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Group E
- description
- patients will receive ultrasound guided ESPB with 30 ml bupivacaine 0.25%.
- interventionNames
- Procedure: Erector spinae plane block (Group E)
- type
- ACTIVE_COMPARATOR
- label
- Group L
- description
- Patients will receive 1.5mg/kg lidocaine 2%; intravenously as a bolus dose then 1.5mg/kg/hr lidocaine infusion using a 50cc syringe pump intraoperatively.
- interventionNames
- Procedure: Lidocaine (drug)
Primary outcomes (1)
- measure
- Measuring serum pro-inflammatory cytokines (IL-1, IL-6) levels in pg/ml.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 30 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Age 30 -60 years. * Female patients. * ASA physical status class I - II. * Elective resectable non metastatic breast cancer. Exclusion Criteria: * Patients with history of sensitivity to the studied drugs. * Patients with cardiac conduction defects. * Patients with major spine deformities. * Patients with severe coagulopathy. * Patients with infection at injection site. * Patients with preexisting myopathy or neuropathy because it can worsen neurological deficits and increase sensitivity to local anaesthetic toxicity. Additionally, it complicates diagnosis of new symptoms and carries higher medicolegal risk due to difficulty distinguishing anaesthesia effects from disease progression. * Psychiatric disease or seizure disorder requiring medication within the previous 2 years. * Opioid tolerant patient. * Cognitive dysfunction. * Body Mass Index ( BMI ) more than 35 kg/m2 or less than 18 kg/m2 .
References
Publications (0)
Data not yet available
No reference posted for this study.